Rituximab and ESHAP as Second-line Therapy for Relapsed or Primary Refractory Diffuse Large B Cell Lymphoma: The Experience of a Single Center in Korea
Korean Journal of Hematology
;
: 309-316, 2007.
Artículo
en Inglés
| WPRIM
| ID: wpr-720999
ABSTRACT
BACKGROUND:
The remission status prior to autologous stem cell transplantation (ASCT) influences the transplantation outcome in patients with relapsed or primary refractory diffuse large B cell lymphoma (DLBCL), a complete response (CR) generally being more favorable than a partial response (PR). This study investigated whether the addition of rituximab to the ESHAP chemotherapy regimen (R-ESHAP) could improve the CR rate in patients with relapsed or primary refractory DLBCL.METHODS:
Retrospective analysis was performed with DLBCL registry data.RESULTS:
Sixteen patients who had previously received one course of chemotherapy were administered R-ESHAP (median 3 cycles; range 1~6). The overall response rate of 75% (CR=50%; PR=25%), was significantly better than that achieved with ESHAP alone in 13 historical controls (31%; P=0.027). The toxicity was tolerable, with two febrile neutropenia episodes in 51 treatment cycles. Seven of the 12 responders to R-ESHAP underwent ASCT with BEAM. After a median follow-up of 17 months, the median survival endpoints have not been reached.CONCLUSION:
R-ESHAP appears to induce high CR rates in relapsed or refractory DLBCL with acceptable toxicity.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Estudios Retrospectivos
/
Estudios de Seguimiento
/
Linfoma de Células B
/
Trasplante de Células Madre
/
Quimioterapia
/
Neutropenia Febril
/
Rituximab
/
Corea (Geográfico)
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Límite:
Humanos
País/Región como asunto:
Asia
Idioma:
Inglés
Revista:
Korean Journal of Hematology
Año:
2007
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS